Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. | ...

Company touted Kisqali's "replacement power" as another blockbuster faces generic competition and expressed optimism about ...

The title of the story has been corrected to reflect that the outlook was raised, instead of the erroneous “outlook cut” ...

The pharmaceutical company raised its full-year profit guidance as ongoing demand for key drugs fueled growth in ...

NVS beats on Q2 earnings, raises 2025 income outlook on strong drug sales, but Cosentyx miss and CFO exit weigh on shares.

Conversations with the Trump administration on its “most favored nation” policy have been productive, the executive said ...

Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

Novartis (NVS) raised its full-year profit outlook thanks to strong demand for some of its key drugs. Novartis CEO Vas ...

Sales growth driven by continued strong performance from Kisqali (+64% cc), Entresto (+22% cc), Kesimpta (+33% cc), Scemblix (+79% cc), Leqvio (+61% cc) and Pluvicto (+30% cc) Core operating income ...

Sales of Kisqali, which treats metastatic breast cancer, surged 64% globally on a constant currency basis in the three months to June, the company said in its second-quarter sales report. That ...

EAST HANOVER, N.J., March 23, 2022 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) approved Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan) (formerly ...